Leo International Precision Health Aktiengesellschaft: Acquisition of six holdings completed by way of capital increase against contributions in kind

Planegg / Martinsried, Germany (pta037/16.12.2025/23:05 UTC+1)

December 16, 2025 – Leo International Precision Health AG ("LIPH" or the "Company", WKN: 549060, ticker symbol: LEOW), an investment and holding company focused on AI-driven precision health assets, announces the completion of the acquisition of its first six portfolio companies.

The acquisitions and the accompanying capital increase through contribution in kind as previously disclosed in the Company's ad-hoc announcement dated November 25, 2025, were implemented and registered in the commercial register of the Düsseldorf Local Court on December 16, 2025. As such, the Company's share capital increased by EUR 50,000.00 to EUR 550,000.00 through a capital increase of EUR 50,000.00 by issuing 50,000 new no-par value bearer shares with full profit participation rights as of January 1, 2025, in exchange for contributions in kind.

The transaction consolidates LIPH's majority shareholdings across key precision health assets and represents a total portfolio valuation of EUR 108 million.

The following entities have now been contributed and integrated into LIPH:

• amiko AI Biomedical Limited, Taiwan (51.00%)
• Danner Laboratory, Inc., USA (51.00%)
• Immune Anima Inc. (UHO Wellness), Taiwan (67.32%)
• Pathomics Health Pte. Ltd., Singapore (51.00%)
• Rehne Biotech (Australia) Pty Ltd, Australia (51.00%)
• Wankang Medical Group (Hong Kong) Co., Limited (Dr. Pain), Hong Kong (100.00%)

-End of the Ad hoc Announcement -

About Leo International Precision Health AG

Leo International Precision Health AG ("LIPH", ticker symbol: LEOW) is a holding company building Europe's first integrated AI-driven healthcare ecosystem. With a strategic focus on AI-driven precision health assets across medtech, healthtech, biotech and healthcare services. LIPH offers investors access to the expanding Asian and global healthcare and life sciences market. By reconfiguring assets, LIPH integrates technology, data, and operations to accelerate medical outcomes and portfolio performance.

For more information, please visit our website.

(end)